Institute of Clinical Research Carries Out Training for Saudi Arabia Government
July 8, 2009-The Institute of Clinical Research (ICR) has opened one of its most popular courses to the world following a visit to the gulf region of Jeddah Saudi Arabia by its education manager.
Sue Fitzpatrick Hon FICR CSci, visited Saudi Arabia to run the ICR’s clinical trials and clinical trials practice course for a group of delegates from some of the leading institutions and pharmaceutical companies based in the country.
Many top pharmaceutical companies have a presence in Saudi Arabia, including Novonordisk, Sanofi-Aventis, AstraZeneca, Pfizer and GlaxoSmithKline but currently only later phase studies are being conducted. In order to attract more commercial attention the region is demonstrating its quality and commitment to conducting good research, beginning with laying these foundations to attract the clinical research market.
Adham Sayed, clinical research associate with Novonordisk attended the course and said: “Having such training in our region would encourage the pharmaceutical companies to have more training for all their employees which will elevate our standards in an international market.”
The course introduces the principles of GCP and regulatory requirements that impact on clinical research, as well as practical aspects of conducting studies to the correct standards.
Sue commented: “It’s great to see Saudi Arabia embracing GCP training. At the moment the regulatory and ethical systems are evolving and this is a golden opportunity for the ICR and Saudi Arabian researchers to work together to develop a solid foundation of quality to build on in the future.”
After the course in Jeddah all of the candidates sat the ICR’s Certificate and Diploma exams and following its success there are plans to arrange several courses in the future.
For further information about the ICR and its range of training and educational courses, visit the website at www.icr-global.org/learning.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
